Status: Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.

Participants needed: 150

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jun 11, 2026Locations: 59

Eligibility criteria

Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional... [+4]

Evidence of lymph node (N2-N3) or metastatic (M1) disease [+5]

Status: Not yet recruiting

Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Participants needed: 90

Trial details

Age: 18-65Biological sex: FemaleType: InterventionalSponsor: Tanta UniversityUpdated: Jan 16, 2026Locations: 1

Eligibility criteria

Age from 18 to 65 years old. [+5]

Pregnant or breastfeeding women. [+6]

Status: Recruiting

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Participants needed: 39

Trial details

Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangdong Provincial People's HospitalUpdated: Aug 12, 2024Locations: 2

Eligibility criteria

Age 18-75 years. [+7]

Active autoimmune disease or history of autoimmune disease. [+15]